Scientists successfully test new skin cancer drug
Sydney: Scientists have successfully tested a new class of drugs in humans that targets a rogue protein responsible for the proliferation of skin cancer, says a study.
The research involves the drug Dz13, a targeted molecular therapy, which was developed at the University of New South Wales (UNSW) and has now been found to be safe in a clinical trial of patients with the common skin cancer, basal-cell carcinoma.
"This is the first report of a drug of this type to be used in humans," says UNSW Medicine`s Professor Levon Khachigian, who has been developing the DNAzyme technology for 10 years.
"It`s a smart drug, which targets a bad protein that controls tumour growth and spread," says Professor Khachigian, the Director of the UNSW Centre for Vascular Research.
The collaborative trial was conducted by researchers from UNSW, the University of Sydney and Royal Prince Alfred Hospital, reports Science Daily. The findings have been published in the journal The Lancet.
More from India
More from World
More from Sports
More from Entertaiment
- Panel discussion on clashes at JNU over Afzal Guru row
- DNA: JNU students clash over Afzal Guru row
- JNU students call terrorist Afzal Guru a martyr amid anti-nationalist slogans
- Panel discussion on clashes at JNU over Afzal Guru row- Part II
- PM Modi breaks protocol to receive Abu Dhabi Crown Prince Al Nahyan
- Drunk girl creates ruckus in Delhi's Connaught Place; arrested - Watch
- JNU erupts over 'Shaheed Afzal Guru', 'Azad Kashmir'; rival student groups clash, police deployed
- AAP poster showing Arvind Kejriwal with Bhindranwale sparks row in Punjab
- Video of Hanumanthappa's rescue that went viral on social media is fake - Watch
- Digangana Suryavanshi chops off her mane on Salman Khan's advice—See pics!